Navigation Links
Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook
Date:2/8/2011

s delivered in 2009.  In the fourth quarter of 2010, more than 15,180 Oncotype DX test results were delivered, an increase of 14 percent, compared with more than 13,340 test results delivered in the same period in 2009.

2011 Financial GuidanceThe company is providing the following financial guidance for the full year ending December 31, 2011:

  • Total revenue of $200 to $210 million
  • Full-year net income of $3 to $5 million
  • Oncotype DX test results delivered of 63,000 to 66,000

  • "In 2011, we expect top-line revenue growth to be primarily driven by the breast cancer franchise as we continue to secure reimbursement for our colon cancer test," said Dean Schorno, Chief Financial Officer of Genomic Health.  "This year we intend to continue an increased level of investment in our business while targeting full year profitability consistent with 2010 levels."

    Fourth Quarter 2010 Highlights:Oncotype DX Breast Cancer Commercial Progress

  • Initiated breast cancer decision impact studies of Oncotype DX with clinical researchers in the United Kingdom and France.
  • Established a contract for estrogen-receptor positive breast cancer patients with Aviva Health Insurance Ireland Limited, a private payor covering approximately 300,000 lives in Ireland.
  • Signed contracts for payment with several hospitals in Germany.
  • Cigna, a large U.S. insurer, extended its coverage to include international members and patients with micrometastases.
  • Breast Cancer Research Treatment published positive results from a Japanese economic evaluation demonstrating that the inclusion of Oncotype DX in Japan's social health insurance benefit package for node-negative and node-positive breast cancer patients would be cost effective.
  • Established first distribution agreement in the Gulf Cooperation Council (GCC) region, in Kuwait.
  • Launched a Japanese langua
    '/>"/>

  • SOURCE Genomic Health, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    3. Personalized Medicine - The Genomic Revolution in Cardiac Care
    4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
    5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
    6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
    7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
    8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
    9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
    10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
    11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific ... NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical ... trial investigating vagus nerve stimulation (VNS) for the ... Ph.D., Professor of Therapeutics and Cardiology and Director ... National de la Sante et de la Recherche ...
    (Date:8/30/2014)... , Aug. 30, 2014   Royal Philips  ... Affiniti, a new ultrasound system designed to ... demands of increasing patient volumes and cost pressures. Making ... 2014 in Barcelona this ... facing more patients with fewer resources deliver high quality ...
    (Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
    Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
    ... Financial Guidance, DUBLIN, Calif., July 1 ... dedicated to the discovery, rapid,development and commercialization ... today commented on the preliminary efficacy,data from ... (decitabine) for,Injection to best supportive care (BSC) ...
    ... SOUTH EASTON, Mass., July 1 Pressure,BioSciences, Inc. ... scientists,from the New York University ("NYU") School of ... on advances they made in the,areas of breast ... The results were generated in studies using PBI,s ...
    Cached Medicine Technology:SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 4Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies 2Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies 3
    (Date:8/30/2014)... 30, 2014 Daily Gossip reveals in its ... Him Desire You program, who shows a unique formula to ... of this method says that the program goes beyond mere ... Him Desire You review indicates that the program was created ... and his great techniques to make a man feel emotionally ...
    (Date:8/30/2014)... 30, 2014 The term nutraceuticals ... Pharameuticals. Nutraceuticals is a source of healthy-dietary supplements ... natural food sources. Nutraceutical ingredients have certain curative ... human body. Nutraceutical health products include factors such ... and more. Although nature is the most bountiful ...
    (Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
    (Date:8/30/2014)... York, New York (PRWEB) August 30, 2014 ... other incretin mimetic claims continue to move forward in ... statement issued by AstraZeneca PLC on July 31, 2014, ... been named in 409 product liability claims that allege ... Court documents indicate that many of these claims are ...
    (Date:8/30/2014)... 30, 2014 In today’s world, a good ... get. Snoring and sleep apnea (a medical problem where the ... their bed partners of the rest they need to face ... population snores and 20 million people in the United States ... diagnosed and treated; and of those treated, many cannot tolerate ...
    Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
    ... Teens who eat less salt lower their long-term risk for high ... finding stems from a computerized projection of what would happen if ... salt from their daily consumption of common processed foods. "Reducing ... that we eat could mean that teenagers live many more years ...
    ... , SATURDAY, Nov. 13 (HealthDay News) -- People who ... increased risk themselves for the potentially deadly heart rhythm ... data from 4,421 participants in the long-term Framingham Heart ... start of the study. Between 1968 and 2007, 440 ...
    ... say that physicians might be drawing conclusions too soon ... whose bodies were for a day initially chilled into ... as therapeutic hypothermia, is one of the few medical ... stoppages, with brain recovery usually assessed three days after ...
    ... HealthDay Reporter , FRIDAY, Nov. 12 (HealthDay News) -- ... have made significant discoveries in the past year that might ... disease in its tracks. That,s some good ... in 1991 as a joint project between the International Diabetes ...
    ... Northwestern Memorial Hospital recently implanted a patient with two ... available for study in humans. VADs are designed to ... or both (BiVAD) at once. This is the first ... the left and right ventricles anywhere in North Americaa ...
    ... (HealthDay News) -- A minor gene variation may be associated with ... study has found. In a recent experiment, Martin Reuter, of ... with this variation in a gene known as COMT gave away ... people with another variation of the gene. The COMT gene ...
    Cached Medicine News:Health News:Study Urges Teens to Cut Down on Salt 2Health News:Study suggests physicians wait longer for brain recovery after hypothermia Rx in cardiac arrest 2Health News:Study suggests physicians wait longer for brain recovery after hypothermia Rx in cardiac arrest 3Health News:Diabetes Research Made Significant Strides in Past Year 2Health News:Diabetes Research Made Significant Strides in Past Year 3Health News:Small assist device used in emergency case as twin, heart booster pumps for first time in US 2
    The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
    FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
    ... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
    ... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
    Medicine Products: